An Open-Label, Dose-Escalation, Safety Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
This purpose of this study is to explore the safety of INCAGN01876 in subjects with advanced or metastatic solid tumors. The study has 2 parts: Part 1 will determine the recommended dose of INCAGN01876, while Part 2 will further evaluate the recommended dose in subjects with certain tumor types (endometrial cancer, melanoma, non-small cell lung cancer, and renal cell carcinoma).
For more information, please contact Incyte Corporation (responsible party for Incyte Europe Sàrl) at +1 (855) 463-3463.
| Condition | All Solid Tumors, Solid Tumors |
|---|---|
| Clinical Study Identifier | TX149864 |
| Sponsor | Incyte Europe Sàrl |
| Last Modified on | 21 April 2022 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.